— Phase 1 Clinical Trial to Evaluate AO-176 for the Treatment of Patients with Select Solid Tumors —
BRISBANE, CA and ST. LOUIS, MO, February 6, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies for cancer, today announced the initiation of a new Phase 1 clinical trial of AO-176 in select solid tumors with the first patient dosed. AO-176 is an anti-CD47 antibody with a best-in-class profile that works by blocking the “don’t eat me” signal and also by directly killing tumor cells, with preferential binding to tumor versus normal cells.
“Dosing the first patient in this new trial is a significant milestone for our Company,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “AO-176 is an anti-CD47 antibody with a best-in-class profile and we are excited to be part of the effort to advance this new class of therapeutics. Our team has worked diligently to bring AO-176 into the clinic, and our aim is to develop this antibody as a new treatment approach for patients with cancer.”
Howard A. “Skip” Burris, III, M.D., President, Clinical Operations, Chief Medical Officer, and Principal Investigator, Sarah Cannon Research Institute, commented, “There is a growing body of research on AO-176, which has demonstrated in preclinical studies a highly differentiated mechanism among the anti-CD47 agents. With greater insights into the number of tumors that overexpress CD47, we are excited to participate in this study to assess this next-generation anti-CD47 antibody’s safety and preliminary efficacy profile.”
Sarah Cannon Research Institute dosed the first patient in the Phase 1 clinical trial of AO-176. The multicenter, open-label, dose-escalation and dose-expansion study is evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of AO-176 in patients with select solid tumors.
AO-176 is a humanized anti-CD47 IgG2 antibody with a best-in-class profile. Arch Oncology’s next-generation anti-CD47 antibody AO-176 is highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class of checkpoint inhibitors. AO-176 works by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, AO-176 also works by directly killing tumor cells. Importantly, AO-176 binds preferentially to tumor cells, instead of to normal cells, and binds even more potently to tumors in their acidic microenvironment (low pH). AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors.
Data presented on AO-176 at recent medical and scientific meetings can be found at https://archoncology.com/newsroom/.
About Arch Oncology
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch’s lead therapy AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. Arch’s leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, and 3×5 Partners. For more information please visit www.archoncology.com.
For Arch Oncology